Manufacturers of the abortion pill ask Supreme Court to restore access by mail
Two manufacturers of the widely used abortion pill mifepristone have urgently appealed to the Supreme Court, seeking to block an appellate court ruling that, just a day prior, halted mail-order access to the medication.
This development marks the most significant shift in US abortion policy since the overturning of Roe v. Wade.
Danco Laboratories, a maker of mifepristone, requested an emergency pause on the 5th U.S. Circuit Court of Appeals decision, arguing the ruling “injects immediate confusion and upheaval into highly time-sensitive medical decisions.” GenBioPro, which produces a generic version of the drug, submitted a similar request to the high court.
The New Orleans-based appeals court’s unanimous decision on Friday represented a substantial victory for abortion opponents.
The ruling mandates that mifepristone be distributed solely in person and at clinics, effectively overriding regulations established by the federal Food and Drug Administration (FDA).
Mary Ziegler, an expert on abortion law and a professor at the University of California at Davis School of Law, commented, “We’re now going to see, I think in a way we haven’t before, what the nation will look like when abortion bans are actually in effect.”
The impact of this ruling extends beyond states with existing abortion bans. While the case progresses through the courts, the decision is in effect nationwide, affecting patients in all states, even those without abortion restrictions.
Josh Thorburn, owner of Eddie’s Pharmacy in Los Angeles, highlighted the challenge, “This is a huge access issue for patients that haven’t got providers close by, or providers close by who are willing to prescribe.”
Legal experts note there is little precedent for a federal court to overrule the scientific regulations of the FDA, and the long-term implications for abortion access remain uncertain.
Mifepristone, approved in 2000, has long been considered a safe and effective method for ending early pregnancies.
It is typically used in conjunction with misoprostol, a drug not impacted by the ruling but less effective on its own.
Surveys indicate that the majority of abortions in the US are medication-induced, with approximately one in four prescribed via telehealth.
Providers suggest that the availability of mifepristone through telehealth has been a factor in abortion numbers remaining stable since Roe was overturned in 2022, making abortion pills and their prescribers key targets for opponents.
The ruling has created uncertainty for providers and patients alike. Mini Timmaraju, president and CEO of Reproductive Freedom for All, stated that providers are “in limbo” but could pivot to using only misoprostol.
She added, “It’s got a chilling effect on providers across the country, and it’s going to have a chilling effect on patients, who are already having a hard time navigating the law state by state, and what they can get and how they can get care.”
Some Democratic-led states have enacted “shield laws” to protect telehealth providers, which are now being tested in civil and criminal cases.
Dr. Angel Foster, a telehealth provider with The Massachusetts Medication Abortion Project, affirmed, “We will do everything in our power to continue providing care to people in all 50 states.”
This case could elevate abortion as a central issue in upcoming midterm elections. Ziegler noted, “This is going to be a pretty significant change in terms of how people experience abortion access, probably as significant as anything we’ve seen since Roe was overturned.”
Recent electoral results show a trend: since Roe was overturned, voters have sided with abortion-rights advocates in 14 out of 17 direct ballot questions.
Louisiana Attorney General Liz Murrill, a Republican, hailed the appellate ruling as a “victory for life.” However, some anti-abortion advocates expressed frustration that Trump did not take action to block the pill’s distribution during his administration.
The FDA, under Trump, approved another generic version of mifepristone last year, a move that displeased some of his allies. Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, remarked, “It’s shameful that the Trump administration’s inaction has forced pro-life states to take their battle to the federal courts,” while also commending the appellate decision.
